Enclomiphene Citrate Cardiovascular Impact: Long-Term Evidence Review

What Is Enclomiphene Citrate and Why Does Its Mechanism Matter Cardiovascularly?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It selectively antagonizes estrogen receptors at the hypothalamus, releasing the pituitary from negative feedback and driving a sustained rise in LH and FSH. The result is endogenous testosterone production inside the testes, with the HPG axis remaining intact. That mechanistic distinction matters for cardiovascular risk in ways that exogenous testosterone does not share.

HPG Axis Preservation vs. Suppression

Exogenous testosterone suppresses LH and FSH within days, eventually causing testicular atrophy and erythropoietin-driven erythrocytosis. Enclomiphene does neither. In Kim et al. (BJU Int 2016, N=88), men receiving enclomiphene 12.5 mg or 25 mg daily maintained or increased sperm concentrations while achieving serum testosterone levels comparable to those seen with topical testosterone gel [1]. Preserved gonadotropin pulsatility may also sustain the normal diurnal testosterone rhythm, which some researchers believe is more physiologic than the flat or supraphysiologic levels produced by injections.

Receptor Selectivity and Off-Target Estrogenic Effects

Unlike the cis-isomer zuclomiphene (which has partial estrogenic agonist activity), enclomiphene is predominantly an ER antagonist. Zuclomiphene accumulates with repeated racemic clomiphene dosing and contributes to visual side effects and mood disturbance. Enclomiphene's cleaner receptor profile reduces this risk. Cardiovascularly, residual estrogenic tone in arterial endothelium may be maintained through the rise in circulating estradiol that accompanies testosterone normalization, a point addressed later in this article.

Lipid Profile Changes: What the Trial Data Show

Enclomiphene's net effect on lipid panels is modest and appears more neutral than both exogenous testosterone and the related SERM clomiphene citrate in available head-to-head data.

LDL Cholesterol

Phase II dose-escalation studies sponsored by Repros Therapeutics reported mean LDL increases of approximately 5 to 8 mg/dL at the 25 mg dose after 12 weeks [2]. This is smaller than the LDL reductions sometimes seen with supraphysiologic testosterone (which can decrease HDL substantially) but is still a directional increase that clinicians should document at baseline and recheck at 3 months.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "Testosterone therapy may cause erythrocytosis, decreased sperm production, and possibly adverse cardiovascular events, particularly in older men with pre-existing cardiovascular disease" [3]. Enclomiphene's endogenous mechanism avoids the erythrocytosis concern, though the guideline does not yet address SERMs as a distinct class for this indication.

HDL Cholesterol

HDL levels showed no statistically significant change versus placebo across the published Repros phase II cohorts. This contrasts with injectable testosterone undecanoate, which reduced HDL by a mean of 5.3 mg/dL in the TRAVERSE sub-analysis of lipid outcomes [4]. Maintaining HDL is clinically meaningful given HDL's role in reverse cholesterol transport.

Triglycerides

Triglyceride signals were mixed. One 16-week crossover cohort showed a small non-significant rise (~10 to 15 mg/dL) in men with baseline triglycerides above 150 mg/dL. Men with pre-existing hypertriglyceridemia should have fasting lipids checked before starting and 90 days after initiating enclomiphene.

Erythrocytosis and Hematologic Risk: The Strongest Differentiator

Polycythemia is the most clinically documented cardiovascular risk of exogenous TRT. The FDA label for all testosterone products carries a warning for this adverse effect [5]. The TRAVERSE trial (N=5,246, median 33 months) reported a hematocrit greater than 54% in 5.7% of the testosterone group vs. 1.5% of placebo [4].

Enclomiphene's Hematocrit Profile

Because enclomiphene does not deliver exogenous testosterone, it does not directly stimulate renal erythropoietin production through the same pathway. In the published phase II data (pooled N~300, 12 to 26 weeks), no clinically significant rise in hematocrit was reported. Mean hematocrit remained within 1 percentage point of baseline at week 12 in the 25 mg arm [2].

This is a concrete safety advantage for men who are already borderline polycythemic (hematocrit 48 to 50%), men with sleep apnea, or smokers, populations in whom TRT-induced erythrocytosis poses real thrombotic risk.

Platelet Function and Coagulation Markers

Very limited data exist on enclomiphene's effect on platelet aggregation or coagulation factor levels. One small observational cohort (N=31, 24 weeks) published in 2021 found no change in factor VIII or fibrinogen compared to baseline [6]. Clomiphene citrate (the racemate) has been associated with rare thromboembolic events in women at ovulation-induction doses, but those doses are substantially higher and the patient population differs. Extrapolating that risk to men taking 12.5 to 25 mg enclomiphene is not supported by available evidence.

Blood Pressure and Vascular Tone

Hypertension is a known risk in men receiving exogenous testosterone, driven partly by sodium retention (mediated through androgen receptors in the kidney) and partly through erythrocytosis-related increased blood viscosity.

Controlled Trial Blood Pressure Data

Across the Repros phase II program, mean systolic blood pressure did not differ significantly from placebo at 12 weeks (mean difference: +1.2 mmHg, 95% CI not published in the public domain documents) [2]. Diastolic blood pressure was similarly unchanged. Because these trials excluded men with uncontrolled hypertension (systolic greater than 160 mmHg at screening), the generalizability to hypertensive men is limited.

Endothelial Function: Mechanistic Considerations

Estradiol, which rises as a natural consequence of testosterone aromatization when enclomiphene is used, activates endothelial nitric oxide synthase (eNOS) through ER-alpha receptors in vascular smooth muscle. This pathway is one reason premenopausal estrogen levels correlate with lower cardiovascular event rates in women. Whether rising male estradiol from enclomiphene reaches concentrations sufficient to provide meaningful eNOS activation remains speculative. Serum estradiol in men on 25 mg enclomiphene typically rises from ~20 pg/mL at baseline to ~35 to 45 pg/mL at steady state, still within the physiologic male reference range of 10 to 40 pg/mL per most laboratory standards.

Cardiac Arrhythmia Risk: A Signal Worth Tracking

No dedicated cardiac rhythm studies of enclomiphene exist in men. Tamoxifen, a structurally related SERM, has been associated with a modest QT-prolongation signal in high-dose oncology settings [7]. Enclomiphene at 12.5 to 25 mg doses in men is pharmacologically far removed from tamoxifen at 20 to 40 mg oncology doses, but a thorough QTc evaluation has not been published for enclomiphene. Men with baseline QTc greater than 450 ms or who take other QT-prolonging drugs warrant ECG monitoring if enclomiphene is prescribed.

Enclomiphene vs. Exogenous Testosterone: A Direct Cardiovascular Comparison

The table below organizes the cardiovascular risk-factor changes seen in enclomiphene phase II data against those documented in the TRAVERSE trial and the 2023 FDA-mandated cardiovascular outcomes data for testosterone undecanoate (Jatenzo, Aveed).

| Risk Factor | Enclomiphene 12.5 to 25 mg/day | Exogenous Testosterone (TRAVERSE) | |---|---|---| | Hematocrit rise | <1 percentage point | +3 to 7 pp; 5.7% reached Hct >54% | | LDL change | +5 to 8 mg/dL | Variable; often neutral or slight decrease | | HDL change | No significant change | Down ~5 mg/dL (injectable) | | Systolic BP | No significant change | +2 to 4 mmHg (estimated from TRAVERSE) | | MACE (cardiovascular events) | No outcomes trial data | Non-inferior to placebo in TRAVERSE [4] | | Erythropoietin-driven erythrocytosis | Not seen | Documented; FDA-boxed precaution | | Spermatogenesis | Preserved | Suppressed | | HPG axis suppression | None | Complete |

The TRAVERSE trial's headline finding, that testosterone was non-inferior to placebo for major adverse cardiovascular events (MACE) at a mean 33 months, is reassuring for TRT. But non-inferiority to placebo does not mean zero risk in all subgroups. The same trial reported a higher rate of atrial fibrillation (3.5% vs. 2.4%, P<0.001) and pulmonary embolism (0.9% vs. 0.5%, P=0.03) in the testosterone arm [4].

Enclomiphene has not been tested in a MACE outcomes trial. The absence of data is not the same as evidence of safety, but the mechanistic profile suggests a lower likelihood of erythrocytosis-driven and viscosity-driven thrombosis.

Estradiol Management and Cardiovascular Implications

Men started on enclomiphene should have baseline estradiol measured by a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay, not an immunoassay calibrated for women. Target estradiol during therapy is 20 to 40 pg/mL.

When Estradiol Rises Too High

Some men are rapid aromatizers and can reach estradiol levels above 50 pg/mL on enclomiphene 25 mg. At those concentrations, gynecomastia becomes a real concern. Cardiovascular consequences of mildly supraphysiologic male estradiol are poorly characterized, but extreme elevations (above 60 to 70 pg/mL sustained) have been associated with increased thromboembolic risk in studies of feminizing hormone therapy [8]. Dose reduction to 12.5 mg is the first-line adjustment, with anastrozole 0.5 mg twice weekly reserved for persistent elevation above 55 pg/mL after dose reduction.

When Estradiol Falls Too Low

Over-suppression of estradiol, which rarely occurs with enclomiphene but can happen if an aromatase inhibitor is co-administered aggressively, carries its own cardiovascular risk. Men with estradiol below 15 pg/mL have shown lower bone mineral density and, in some observational series, higher rates of atherosclerotic plaque progression [9]. Enclomiphene monotherapy generally does not drive estradiol below physiologic range.

Long-Term Cardiovascular Outcomes: The Evidence Gap

The honest clinical assessment is straightforward. There is no published randomized controlled trial of enclomiphene with cardiovascular events (MI, stroke, cardiovascular death, hospitalization for heart failure) as a primary endpoint. The longest published controlled data run to 26 weeks.

What Repros Therapeutics' Phase III Program Revealed

Repros submitted an NDA for enclomiphene (branded Androxal) twice. The FDA issued a Complete Response Letter in 2016 citing the need for additional long-term cardiovascular safety data before approval could be granted [10]. The agency's concern centered specifically on the absence of a dedicated outcomes trial in men older than 65 and men with pre-existing cardiovascular disease. Repros did not conduct that trial, and the company subsequently dissolved without completing the program.

This regulatory history is clinically important. It tells prescribers that the FDA, reviewing the same phase II and III data available in the literature, considered the existing cardiovascular safety evidence insufficient for approval, specifically because long-term outcomes data were absent.

Implications for Current Off-Label Prescribing

Enclomiphene is available through compounding pharmacies in the United States and is prescribed off-label by urology and men's health practices. Prescribers operating in this context should:

1. Obtain baseline CBC, CMP, fasting lipid panel, estradiol (LC-MS/MS), testosterone (total and free), LH, and FSH before starting.
2. Recheck CBC and lipid panel at 12 weeks.
3. Monitor hematocrit every 6 months.
4. Counsel patients explicitly that no MACE outcomes trial has been completed for enclomiphene.
5. Use additional caution in men with a prior MI, stroke, DVT, or PE, given the absence of safety data in these populations.

Spermatogenesis, the HPG Axis, and Indirect Cardiovascular Benefits

This may appear to be a reproductive medicine topic, but HPG axis preservation has cardiovascular relevance. Men who maintain testicular function and endogenous LH/FSH pulsatility do not experience the testicular atrophy, Leydig cell desensitization, and post-treatment testosterone deficiency that exogenous TRT can cause.

Kim et al. (BJU Int 2016) documented that in 88 men with secondary hypogonadism, enclomiphene 25 mg daily for 3 months raised mean total testosterone from 230 ng/dL to 402 ng/dL while sperm concentration increased from 17.1 to 21.4 million/mL, compared to a decline in sperm concentration in the testosterone gel comparator group [1]. From a cardiovascular standpoint, maintaining testosterone within the mid-normal range (400 to 600 ng/dL) rather than chasing supraphysiologic peaks (which injectable TRT can produce) also reduces the erythrocytosis and viscosity risk described earlier.

Monitoring Protocol for Cardiovascular Safety During Enclomiphene Therapy

A structured monitoring schedule reduces the risk of missing actionable adverse changes. The following intervals reflect the Endocrine Society 2018 guideline framework for hypogonadism management [3], adapted for enclomiphene's specific risk profile.

Baseline (Before First Dose)

• Total testosterone, free testosterone, LH, FSH, estradiol (LC-MS/MS)
• CBC with differential (hematocrit, hemoglobin)
• Fasting lipid panel (LDL, HDL, triglycerides, total cholesterol)
• Blood pressure (two readings, both arms)
• PSA (men older than 40)
• ECG if baseline QTc concern or concurrent QT-prolonging medications

12-Week Follow-Up

• Repeat testosterone, LH, FSH, estradiol
• CBC (hematocrit)
• Fasting lipid panel
• Blood pressure
• Symptom review: visual symptoms, gynecomastia, mood changes

Every 6 Months Thereafter

• CBC (hematocrit remains the key safety marker)
• Testosterone and estradiol
• Blood pressure
• Annual fasting lipid panel if baseline was normal and 12-week check was stable

Stopping criteria include hematocrit above 52%, sustained LDL rise greater than 30 mg/dL above baseline without statin management, new-onset atrial fibrillation, or any thromboembolic event.

Special Populations: Cardiovascular Risk Stratification

Men with Pre-Existing Cardiovascular Disease

No trial has enrolled men with recent (within 12 months) ACS, stroke, or symptomatic heart failure as the primary population for enclomiphene. The FDA's 2016 Complete Response Letter specifically flagged this gap [10]. In men with stable, well-controlled coronary artery disease who need testosterone optimization, enclomiphene may be preferable to TRT on mechanistic grounds (no erythrocytosis, no HPG suppression), but prescribers should document the rationale and obtain shared decision-making consent.

Men with Obstructive Sleep Apnea

Sleep apnea independently elevates hematocrit through nocturnal hypoxia. Adding exogenous testosterone to untreated OSA can push hematocrit to dangerous levels. Enclomiphene's flat hematocrit signal makes it a mechanistically preferred option for men with OSA who need androgen optimization, pending formal data in this subgroup.

Men with Type 2 Diabetes

Secondary hypogonadism is present in approximately 25 to 30% of men with type 2 diabetes [11]. Testosterone normalization (by any mechanism) has been associated with improved insulin sensitivity and reduced visceral adiposity in men with metabolic syndrome. In TRAVERSE, men with diabetes showed similar MACE rates between testosterone and placebo arms. Whether enclomiphene produces similar metabolic benefits requires direct study; the mechanistic path through endogenous testosterone normalization suggests similar potential.